Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1794157rdf:typepubmed:Citationlld:pubmed
pubmed-article:1794157lifeskim:mentionsumls-concept:C0205039lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0038218lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0039542lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0018810lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0232108lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0175566lld:lifeskim
pubmed-article:1794157lifeskim:mentionsumls-concept:C0240526lld:lifeskim
pubmed-article:1794157pubmed:issue3lld:pubmed
pubmed-article:1794157pubmed:dateCreated1992-4-6lld:pubmed
pubmed-article:1794157pubmed:abstractTextOur study investigated the differential effects of continuous or unequal day-night terbutaline dosing on circadian bronchial patency, heart rate, and arterial pressure in severe acute asthma. Forty-five hospitalized asthmatic patients (19 women and 26 men, mean age 45.4 years, mean weight 63.5 kg) were included in this multicenter study. Three groups of patients (corresponding to three dosing schedules) were randomized; the three groups were comparable, since no statistically significant difference was detected in the age, weight, or peak expiratory flow values at the beginning of the study. In order to reach immediately the concentrations of terbutaline corresponding to the desired unequal day-night concentrations, a theoretical pharmacokinetic simulation was done to predict the outcome in terms of the plasma concentrations after the three dosing regimens; the results of this simulation allowed us to calculate the initial bolus dose to be given over 5 min to groups A, B, and C, i.e., 1.47, 2.94, and 4.41 micrograms/kg, respectively. This bolus was given to all patients at 0700 h, the beginning of the study.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1794157pubmed:languageenglld:pubmed
pubmed-article:1794157pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1794157pubmed:citationSubsetIMlld:pubmed
pubmed-article:1794157pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1794157pubmed:statusMEDLINElld:pubmed
pubmed-article:1794157pubmed:issn0742-0528lld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:BruguerolleBBlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:VervloetDDlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:ArnaudAAlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:LeonardelliMMlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:OrlandoJ PJPlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:ReynaudMMlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:LagierFFlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:Philip-JoetFFlld:pubmed
pubmed-article:1794157pubmed:authorpubmed-author:PiersonFFlld:pubmed
pubmed-article:1794157pubmed:issnTypePrintlld:pubmed
pubmed-article:1794157pubmed:volume8lld:pubmed
pubmed-article:1794157pubmed:ownerNLMlld:pubmed
pubmed-article:1794157pubmed:authorsCompleteYlld:pubmed
pubmed-article:1794157pubmed:pagination194-202lld:pubmed
pubmed-article:1794157pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:meshHeadingpubmed-meshheading:1794157-...lld:pubmed
pubmed-article:1794157pubmed:year1991lld:pubmed
pubmed-article:1794157pubmed:articleTitleUnequal day-night terbutaline i.v. dosing in acute severe asthma: effect on nocturnal bronchial patency, heart rate, and arterial pressure.lld:pubmed
pubmed-article:1794157pubmed:affiliationMedical and Clinical Pharmacology Laboratory, Faculty of Medicine, Marseille, France.lld:pubmed
pubmed-article:1794157pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1794157pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1794157pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1794157pubmed:publicationTypeMulticenter Studylld:pubmed